Evercore ISI Group Downgrades BELLUS Health to In-Line, Lowers Price Target to $14.75
Evercore ISI Group Downgrades BELLUS Health to In-Line, Lowers Price Target to $14.75
Evercore ISI Group 將BELLUS Health的評級下調至聯線，將目標價下調至14.
Evercore ISI Group analyst Josh Schimmer downgrades BELLUS Health (NASDAQ:BLU) from Outperform to In-Line and lowers the price target from $24 to $14.75.
Evercore ISI Group分析師喬什·席默將BELLUS Health（納斯達克股票代碼：BLU）的評級從跑贏大盤下調至持平，並將目標股價從24美元下調至14.75美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。